RJA
KRRO icon

Raymond James & Associates’s Korro Bio KRRO Stock Holding History

Raymond James & Associates’s Portfolio KRRO Stock Details KRRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-520
Closed -$9K – 3867
2023
Q2 		$9K Buy
520
+100
+24% +$1.94K ﹤0.01% 3812
2023
Q1 		$10.6K Buy
+420
New +$47.9K ﹤0.01% 3837

Other funds holding KRRO

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's KRRO Position: Q3 2023 in Review

Raymond James & Associates sold out of Korro Bio (KRRO) in Q3 2023, closing a stake of 520 shares — an estimated $9K sold.

Raymond James & Associates first reported a position in KRRO in Q1 2023 and held it in 2 quarters. The position peaked at $10.6K in Q1 2023. 41 funds tracked by Wall St. Rank hold KRRO as of Q3 2023.

  • Raymond James & Associates reported no remaining Korro Bio position as of Q3 2023 after selling out during the quarter.
  • Raymond James & Associates sold 520 Korro Bio shares in Q3 2023, an estimated $9K.
  • Raymond James & Associates first reported a position in Korro Bio in Q1 2023 and held it in 2 quarters.
  • Raymond James & Associates's Korro Bio position peaked at $10.6K in Q1 2023.
  • 41 funds tracked by Wall St. Rank held Korro Bio as of Q3 2023.

Based on Raymond James & Associates's 13F filing for Q3 2023, filed 24 Oct 2023.